Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin
The prophylactic effect of low-dose heparin on postoperative fatal and on clinically apparent but non-fatal thromboembolic complications was studied in a double-blind, prospective, randomised study comprising 1296 patients. 16 out of 653 patients in the placebo group had such complications within th...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1978-05, Vol.1 (8074), p.1115-1116 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1116 |
|---|---|
| container_issue | 8074 |
| container_start_page | 1115 |
| container_title | The Lancet (British edition) |
| container_volume | 1 |
| creator | Kiil, J Axelsen, F Andersen, D |
| description | The prophylactic effect of low-dose heparin on postoperative fatal and on clinically apparent but non-fatal thromboembolic complications was studied in a double-blind, prospective, randomised study comprising 1296 patients. 16 out of 653 patients in the placebo group had such complications within the treatment period of 1 week, compared with 4 out of 643 in the heparin group. This difference was statistically significant (P less than 0.05). 4 cases in the placebo group and 1 in the heparin group were fatal. After prophylactic treatment had been stopped at the end of the first postoperative week, the rate of thromboembolic complications was equal for the 2 groups. Low-dose heparin prophylaxis is thus effective and should be given routinely in patients aged over 40 years; it should also be given for more than 1 week in patients not ambulant by then. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73997064</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73997064</sourcerecordid><originalsourceid>FETCH-LOGICAL-p513-a5fe5b1247ec5cb3ee3d1774bd2fa18574caf87fb4d7e98490de031fe63645183</originalsourceid><addsrcrecordid>eNotkD1PwzAYhD1QQSn8AhZPbJHs2o6TEVV8SZVg6B69jt8QIyc2dlLovyeCTjfc6dHdXZA145IVpRblFbnO-ZMxJkumLslKa8nFmsB7CrE_efhxmcIHuDFPNIY8hYgJJndEGmc_hBHSieJggnd5oDBaahFjcUQ30qlPYXHyQjAn6sN3YUNG2mOE5MYbsurAZ7w964Ycnh4Pu5di__b8unvYF1FxUYDqUBm-lRpb1RqBKCxfOhq77YBXSssWukp3RlqNdSVrZpEJ3mEpSql4JTbk_h8bU_iaMU_N4HKL3sOIYc6NFnWtWSmX4N05OJsBbROTG5Zxzd8h4hcWFF3c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73997064</pqid></control><display><type>article</type><title>Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kiil, J ; Axelsen, F ; Andersen, D</creator><creatorcontrib>Kiil, J ; Axelsen, F ; Andersen, D</creatorcontrib><description>The prophylactic effect of low-dose heparin on postoperative fatal and on clinically apparent but non-fatal thromboembolic complications was studied in a double-blind, prospective, randomised study comprising 1296 patients. 16 out of 653 patients in the placebo group had such complications within the treatment period of 1 week, compared with 4 out of 643 in the heparin group. This difference was statistically significant (P less than 0.05). 4 cases in the placebo group and 1 in the heparin group were fatal. After prophylactic treatment had been stopped at the end of the first postoperative week, the rate of thromboembolic complications was equal for the 2 groups. Low-dose heparin prophylaxis is thus effective and should be given routinely in patients aged over 40 years; it should also be given for more than 1 week in patients not ambulant by then.</description><identifier>ISSN: 0140-6736</identifier><identifier>PMID: 77413</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Age Factors ; Aged ; Clinical Trials as Topic ; Female ; Heparin - administration & dosage ; Heparin - therapeutic use ; Humans ; Injections, Subcutaneous ; Leg - blood supply ; Male ; Middle Aged ; Pelvis - blood supply ; Placebos ; Population ; Postoperative Complications - prevention & control ; Prospective Studies ; Pulmonary Embolism - prevention & control ; Research Design ; Thrombophlebitis - prevention & control</subject><ispartof>The Lancet (British edition), 1978-05, Vol.1 (8074), p.1115-1116</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/77413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kiil, J</creatorcontrib><creatorcontrib>Axelsen, F</creatorcontrib><creatorcontrib>Andersen, D</creatorcontrib><title>Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>The prophylactic effect of low-dose heparin on postoperative fatal and on clinically apparent but non-fatal thromboembolic complications was studied in a double-blind, prospective, randomised study comprising 1296 patients. 16 out of 653 patients in the placebo group had such complications within the treatment period of 1 week, compared with 4 out of 643 in the heparin group. This difference was statistically significant (P less than 0.05). 4 cases in the placebo group and 1 in the heparin group were fatal. After prophylactic treatment had been stopped at the end of the first postoperative week, the rate of thromboembolic complications was equal for the 2 groups. Low-dose heparin prophylaxis is thus effective and should be given routinely in patients aged over 40 years; it should also be given for more than 1 week in patients not ambulant by then.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Clinical Trials as Topic</subject><subject>Female</subject><subject>Heparin - administration & dosage</subject><subject>Heparin - therapeutic use</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Leg - blood supply</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pelvis - blood supply</subject><subject>Placebos</subject><subject>Population</subject><subject>Postoperative Complications - prevention & control</subject><subject>Prospective Studies</subject><subject>Pulmonary Embolism - prevention & control</subject><subject>Research Design</subject><subject>Thrombophlebitis - prevention & control</subject><issn>0140-6736</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1978</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotkD1PwzAYhD1QQSn8AhZPbJHs2o6TEVV8SZVg6B69jt8QIyc2dlLovyeCTjfc6dHdXZA145IVpRblFbnO-ZMxJkumLslKa8nFmsB7CrE_efhxmcIHuDFPNIY8hYgJJndEGmc_hBHSieJggnd5oDBaahFjcUQ30qlPYXHyQjAn6sN3YUNG2mOE5MYbsurAZ7w964Ycnh4Pu5di__b8unvYF1FxUYDqUBm-lRpb1RqBKCxfOhq77YBXSssWukp3RlqNdSVrZpEJ3mEpSql4JTbk_h8bU_iaMU_N4HKL3sOIYc6NFnWtWSmX4N05OJsBbROTG5Zxzd8h4hcWFF3c</recordid><startdate>19780527</startdate><enddate>19780527</enddate><creator>Kiil, J</creator><creator>Axelsen, F</creator><creator>Andersen, D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19780527</creationdate><title>Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin</title><author>Kiil, J ; Axelsen, F ; Andersen, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p513-a5fe5b1247ec5cb3ee3d1774bd2fa18574caf87fb4d7e98490de031fe63645183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1978</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Clinical Trials as Topic</topic><topic>Female</topic><topic>Heparin - administration & dosage</topic><topic>Heparin - therapeutic use</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Leg - blood supply</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pelvis - blood supply</topic><topic>Placebos</topic><topic>Population</topic><topic>Postoperative Complications - prevention & control</topic><topic>Prospective Studies</topic><topic>Pulmonary Embolism - prevention & control</topic><topic>Research Design</topic><topic>Thrombophlebitis - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kiil, J</creatorcontrib><creatorcontrib>Axelsen, F</creatorcontrib><creatorcontrib>Andersen, D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kiil, J</au><au>Axelsen, F</au><au>Andersen, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>1978-05-27</date><risdate>1978</risdate><volume>1</volume><issue>8074</issue><spage>1115</spage><epage>1116</epage><pages>1115-1116</pages><issn>0140-6736</issn><abstract>The prophylactic effect of low-dose heparin on postoperative fatal and on clinically apparent but non-fatal thromboembolic complications was studied in a double-blind, prospective, randomised study comprising 1296 patients. 16 out of 653 patients in the placebo group had such complications within the treatment period of 1 week, compared with 4 out of 643 in the heparin group. This difference was statistically significant (P less than 0.05). 4 cases in the placebo group and 1 in the heparin group were fatal. After prophylactic treatment had been stopped at the end of the first postoperative week, the rate of thromboembolic complications was equal for the 2 groups. Low-dose heparin prophylaxis is thus effective and should be given routinely in patients aged over 40 years; it should also be given for more than 1 week in patients not ambulant by then.</abstract><cop>England</cop><pmid>77413</pmid><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1978-05, Vol.1 (8074), p.1115-1116 |
| issn | 0140-6736 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73997064 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Age Factors Aged Clinical Trials as Topic Female Heparin - administration & dosage Heparin - therapeutic use Humans Injections, Subcutaneous Leg - blood supply Male Middle Aged Pelvis - blood supply Placebos Population Postoperative Complications - prevention & control Prospective Studies Pulmonary Embolism - prevention & control Research Design Thrombophlebitis - prevention & control |
| title | Prophylaxis against postoperative pulmonary embolism and deep-vein thrombosis by low-dose heparin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T01%3A49%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prophylaxis%20against%20postoperative%20pulmonary%20embolism%20and%20deep-vein%20thrombosis%20by%20low-dose%20heparin&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Kiil,%20J&rft.date=1978-05-27&rft.volume=1&rft.issue=8074&rft.spage=1115&rft.epage=1116&rft.pages=1115-1116&rft.issn=0140-6736&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E73997064%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73997064&rft_id=info:pmid/77413&rfr_iscdi=true |